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Dr. Stonestreet presented a case of an infant who was born
25 weeks gestation by spontaneous vaginal delivery with
Apgar scores of 11 and 55. The infant was intubated
because of decreased respiratory effort. He developed a
pneumothorax on day 2 of life and bilateral grade 4 intra-
ventricular hemorrhages. This case was used as a clinical
example of infants that develop intraventricular hemor-
rhage. There is a large increase in brain maturation that
occurs over the interval when infants develop intraven-
tricular hemorrhage. From 23–32 weeks of gestation,
important processes such as branching synaptagenesis,
programmed cell death and reorganization of synapses
are occurring in premature infants. The grading scale of
LuAnn Papile has long been used to categorize grade of
intraventricular hemorrhage. Fortunately, the incidence of
intraventricular hemorrhage has decreased from the
1980's until 2006. In 2006, the incidence of all types of
intraventricular hemorrhage were at 36 percent with
severe types (Grades 3 and 4) representing 14 percent of
infants <1000 gm. Many clinical prenatal and postnatal
factors predispose infants to intraventricular hemorrhage.
Factors that can be protective against the neonatal devel-
opment of intraventricular hemorrhage include maternal
transport, optimal delivery, decreased use of ventilation
where possible, limitation of intravenous volume boluses,
limitation of the use of Dopamine, limitation of treat-
ment with bicarbonate, avoiding pneumothorax and gen-
tle handling. Hemorrhagic hydrocephalus occurs 1–3
weeks after intraventricular hemorrhage. In sixty-five per-
cent of infants that develop post-hemorrhagic, it hydro-
cephalus resolves within 4 weeks. Fifteen to twenty
percent of these infants require a shunt for post-hemor-
rhagic hydrocephalus. Serial lumbar punctures do not
prevent the need for a shunt or improve neurologic out-
comes. However, serial lumbar punctures and ventricular
taps may be necessary as a temporizing effort. Futile ther-
apies for post-hemorrhagic hydrocephalus include early
lumbar punctures, the use of diuretics and fibrinolytic
therapy to prevent shunt dependence. An intraventricular
shunt may be necessary for infants with post-hemorrhagic
hydrocephalus. However, the timing of the shunt place-
ment is based largely upon clinical judgment and the size
of the ventricles. When the ventricular dilation is 4 ml
higher than the 97th percentile for ventricular width at a
given, a shunt is most likely indicated. Recent data sug-
gests that infants that require shunting for post-hemor-
rhagic hydrocephalus have poorer neurodevelopmental
outcomes than infants with severe hydrocephalus that do
not require a shunt. Nonetheless, at age 5 the infant that
was presented by Dr. Stonestreet is doing quite well and is
mainstreaming in a normal school environment. Early
intervention therapies can help with the neurologic devel-
opment even in infants that develop post-hemorrhagic
hydrocephalus.
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